{{Rsnum
|rsid=9909104
|Gene=SHMT1
|Chromosome=17
|position=18344707
|Orientation=plus
|GMAF=0.3122
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=SHMT1
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 5.3 | 40.7 | 54.0
| HCB | 7.3 | 40.1 | 52.6
| JPT | 3.5 | 40.7 | 55.8
| YRI | 20.4 | 44.2 | 35.4
| ASW | 24.6 | 49.1 | 26.3
| CHB | 7.3 | 40.1 | 52.6
| CHD | 8.3 | 39.4 | 52.3
| GIH | 4.0 | 34.7 | 61.4
| LWK | 26.4 | 40.0 | 33.6
| MEX | 6.9 | 29.3 | 63.8
| MKK | 16.7 | 52.6 | 30.8
| TSI | 3.9 | 46.1 | 50.0
| HapMapRevision=28
}}{{PMID|18381459|OA=1
}} 829 Caucasian cases with primary epithelial ovarian cancer and 941 frequency-matched unaffected controls 
*Each copy of the minor allele in SHMT1 intron 5 A>G ([[rs9909104]]) was associated with epithelial ovarian cancer [odds ratio (OR), 1.2; 95% confidence interval (95% CI), 1.0-1.4; P trend = 0.02; FPRP = 0.16] and a 5-SNP SHMT1 haplotype was associated with decreased risk (P = 0.01; FPRP = 0.09).

{{PMID Auto
|PMID=23940529
|Title=Roles of genetic polymorphisms in the folate pathway in childhood acute lymphoblastic leukemia evaluated by bayesian relevance and effect size analysis
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}